STUDresearch · Peptide

Cartalax

Also known as

AED peptide · Ala-Glu-Asp · Alanyl-glutamyl-aspartic acid · T-31 · AC-4 · AC4 · cartilage bioregulator · Cartalax Cytogen · Khavinson cartilage peptide · cartilage and bone tissue bioregulator

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Some talk Mixed Oral / Sublingual / SubQ Longevity & bioregulators

Discussed for cartilage and connective tissue, with oral or injectable exposure rather than proven local delivery.

What people say Cartalax is synthetic AED (Ala-Glu-Asp), discussed as a cartilage and bone bioregulator. Oral products and lyophilized powder are not equivalent to tissue-extract products such as Sigumir, and direct human joint evidence is very thin. Doses people talk about

Classic multi-milligram chart10 mg/day injection for about 10 days

Repeated Russian-style secondary chart, not a registered dose standard.

Split multi-milligram chart5 mg twice daily for about 10–20 days

Community split-total chart rather than an efficacy comparison.

Lower SubQ charts0.2–2 mg/day SubQ for about 10–20 days

Western community and vendor range, not established human dosing.

Microgram and weight-scaled charts100–250 mcg/day SubQ; sparse 10–20 mcg/kg talk

Conflicting low charts and calculator talk; not a human protocol.

Oral product calendar2 capsules/day for about 30 days; later 10-day pulses in some product literature

Oral Cytogen package language; not interchangeable with lyophilized AED powder.

Rows retain the original route and course context. No controlled human dose-response or cross-route conversion was located.

Half-life & effect duration

Half-life in the body: Community estimateAbout 30 minutes
Felt duration people report: Joint reportsStrong hip-arthritis benefit in one account
Other accountsNo benefit across repeated 30-day courses or at a 2-month follow-up

Timing context & sources

How it may feel Community reports range from no discernible effect after one or two 30-day runs to a strong hip-arthritis relief claim. Surgery, training, repair-peptide stacks and uncertain product identity make onset and causation hard to isolate.

Cycles people discuss Charts range from classic 10-day blocks to 10–20-day injectable courses and 30-day oral courses, often repeated every few months. That course culture is not a validated maintenance schedule. Timing Morning daily use and split charts are conventions, not pharmacokinetic results. No measured Cartalax/AED half-life was located, and course-level joint changes cannot be converted into a single-dose clock. Stacks BPC-157, TB-500, GHK-Cu and KPV commonly appear beside Cartalax. Multi-vial use, rehabilitation and changing load make both benefits and side effects difficult to attribute. Watch for Evidence gap: Sparse modern controlled human efficacy and safety data — Russian observational and in-vitro signals do not equal FDA-level OA proof.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

No measured AED/Cartalax half-life was located in the reviewed evidence ledger.

A commonly repeated 30-minute figure was not connected to a primary PK source.

The ledger is a secondary audit; its underlying searches were not independently reproduced in full during this pass.

Vialog Cartalax evidence ledger (opens in a new tab)Identity lines 28–36; half-life and claim audit lines 58–70; unknowns and trial audit lines 110–131; references lines 132–136.Secondary evidence audit, not a primary trial or PK study. It distinguishes pure AED from the Sigumir extract but does not independently prove absence from every database.

Felt duration people report

The inspected reports do not establish a typical onset or a single-dose felt duration.

The thread includes a strong hip-arthritis benefit claim without dose, a 30-on/30-off/30-on null report, and a surgery-confounded two-month null follow-up.

Small self-report set, product uncertainty, missing route/dose details and major co-interventions prevent causal timing inference.

Cartalax - experience/dosage (opens in a new tab)Original post lines 78–94; railroadiron lines 116–129; josrios3 lines 132–138; original-poster follow-up lines 179–185.Small self-report thread with missing route and dose details, surgery and other recovery-stack confounding, and no objective cartilage endpoint.

What people say 14

Joint comfort (community): Easier movement, quieter knees/hips, or less activity-related ache over multi-week windows after short courses — effects usually described as modest and gradual. forum
Morning stiffness / mobility: Range-of-motion or warm-up ease more often than acute pain knockout; users compare feel to “less creaky” rather than “numbed.” forum
Athlete overuse: Faster return-to-load or better training-joint tolerance after cyclic courses is discussed; confounded by deloads, PT, and stacks. anecdote
vs BPC-157 / TB-500: Framed as aging-joint calendar bioregulator (short intensive courses, subtle residual effect) versus continuous angiogenic/cell-migration repair peptides with faster subjective timelines. forum
vs Sigumir: Product literature sometimes positions Sigumir as more cartilage-specialist and Cartalax as broader musculoskeletal/cartilage-and-bone; both are bioregulator-class, not interchangeable proven drugs. forum
Training load continuity: Some lifters/runners report better joint-loading tolerance with concurrent PT or deload — highly confounded n=1 logs. anecdote
Feel profile: Gradual and subtle versus NSAIDs, corticosteroid injections, or GH-axis compounds; many “non-responders” after one cycle. forum
What it is not claimed to fix well: Bone-on-bone end-stage OA, acute soft-tissue tears needing repair peptides, or same-day competition analgesia — community realism is low for those. forum
OA / function evidence gap: The checked citation trail did not locate a human osteoarthritis cohort given pure AED/Cartalax that supports the quoted 20–40% pain or 15–30% mobility figures. The indexed human cohort used the separate Sigumir cartilage extract within multi-component care; do not transfer its outcomes or schedule to Cartalax. trial
Elderly flexibility narratives: Product/secondary tables sometimes summarize elderly (e.g., ~60–75) multi-cycle flexibility/pain shifts after 10 mg × 10 days × several cycles — same low-rigor observational tier. trial
Cartilage / ECM (preclinical): Chondrocyte and mesenchymal models link AED to matrix-related gene shifts (collagen/aggrecan/proteoglycan talk) and reduced catabolic enzyme signaling — cell-level, not imaging-proven human regrowth. lab
MSC aging gene panel: Human mesenchymal stem-cell aging culture work reports AED modulation of genes including IGF1, FOXO1, TERT, TNKS2, and NFκB — mechanistic, not a joint outcome trial. lab
Senescence / apoptosis talk: Secondary research summaries discuss lower p16/p21/p53-class senescence markers and reduced chondrocyte apoptosis under inflammatory stress in models — theoretical longevity-joint angle. lab
Type XI collagen hook: Ala-Glu-Asp sequence homology to type XI collagen is a frequent story hook for “cartilage targeting,” not clinical regen proof. lab

Doses people talk about 14

Classic Russian-style injectable (high multi-mg course): ~10 mg daily × ~10 consecutive days (~100 mg peptide per cycle) is the most-repeated “traditional bioregulator” figure in secondary guides and longevity blogs. forum
Split multi-mg: ~5 mg twice daily across ~10–20 day blocks when users split the same multi-mg daily total. forum
Western research-peptide mid charts: Many vendor protocol pages list ~1–2 mg subcutaneous once daily for ~10–20 days (morning injection common). forum
Low-dose community band: Honest secondary dosing guides summarize community practice as roughly ~0.2–2 mg/day subq for short courses — still convention, not PK-validated. forum
Low mcg charts (conflict zone): Some Western peptide tables list ~100–250 mcg (0.1–0.25 mg) subq daily — two orders of magnitude below the 10 mg Russian-style figure; mg-vs-mcg mix-ups and chart copy errors are a recurring community warning. forum
Oral Cytogen capsules (product literature): Typical intensive course: 2 capsules/day for ~30 days (60 capsules), then maintenance 2 capsules/day for ~10 days (~20 capsules) every ~3 months; more severe need talk raises re-runs to every 1–2 months. forum
Oral/sublingual vs injectable dose culture: Secondary guides sometimes suggest higher oral/sublingual totals (e.g., ~15–20 mg discussed vs ~10 mg injectable) because gut/mucosal bioavailability is assumed lower — estimates (~30–50% oral, ~40–60% sublingual, ~80–90% subq) are community/vendor guesses, not published Cartalax human PK. forum
Course total math (10 mg × 10 d): Classic multi-mg calendar ≈ ~100 mg lyophilized peptide per cycle; at 20 mg vials that implies multiple vials per course (e.g., five 20 mg vials if 10 mg/day) — cost is a frequent forum complaint. forum
Course total math (1–2 mg × 10–20 d): Mid charts use far less peptide (~10–40 mg per course), which is why Western vendor vials (10–20 mg) can cover a full block. forum
Intra-articular advanced talk (sparse/marketing): A minority of specialized sites discuss weekly intra-articular loading for ~3 weeks then monthly maintenance — not mainstream forum practice and not backed by registered IA trials for Cartalax. forum
Timing: Morning once-daily is the default injectable chart; AM/PM splits appear when multi-mg totals are divided. forum
Uncertainty rule: Oral Cytogen capsules, sublingual drops, and lyophilized AED powder are not interchangeable by brand name alone — always resolve sequence (AED), form, and unit before comparing logs. forum
Weight-scaled research talk (sparse): Occasional calculator pages cite ~10–20 mcg/kg (e.g., ~700–1,400 mcg for a ~70 kg adult) for “tissue regeneration” research framing — not a controlled human protocol. forum
Framing: Community, vendor-chart, and product-label ranges only — not prescriptions, not trial-established human doses. No ClinicalTrials.gov dose standard exists for Cartalax. forum

How it may feel 8

Days 1–3: The inspected thread does not establish one typical onset. It contains a strong hip-arthritis improvement claim without a recorded dose, a 30-day-on/30-day-off/30-day-on null report, and a surgery-confounded two-month null follow-up; none proves early cartilage repair or what most users feel. forumanecdote
Days 4–10 (classic short course): Mild stiffness ease, easier warm-up, or still nothing — checkpoint often at course end, not day 2. forum
End of 10–20 day block: Primary reassessment — quieter joints vs “subtle/absent”; escalate expectation-setting before dose escalation. forum
Weeks 2–8 post-course: Residual benefit is commonly framed as continuing after dosing stops (bioregulator “signal then off” lore). forum
Weeks 4–12 (oral intensive starts): Oral Cytogen 30-day intensives are described as slower to judge than injectable short blocks; still not NSAID-speed. forum
Months 2–6 with re-runs: Clearer functional stories often involve 2–3 cyclic courses plus load management — single-cycle miracles are minority claims. forum
Months 3–6 calendar: Re-run a 10-day (or product-label 10–30 day) block ~2–4×/year when stiffness or high joint-load season returns. forum
No change after 2–3 cycles: Community advice is to re-check diagnosis (meniscus, inflammatory arthritis, alignment), training load, purity/form (oral vs powder), and stack confounds — not automatic multi-mg escalation. forum

Cycles people discuss 9

Short blocks dominate: 10 consecutive days is the classic Khavinson-style pattern shared with other bioregulators (Epitalon-class calendars). forum
Extended injectable windows: 10–20 day courses are common on Western vendor charts (1–2 mg/day culture). forum
Oral intensive then pulse: Product guides: ~30-day intensive (2 caps/day), then ~10-day pulses every ~3 months (sometimes denser if “severe need”). forum
Off periods / yearly cadence: Injectable multi-mg lore often repeats every ~3–6 months (~2–4 cycles first year; ~2–3/year maintenance); intensive talk shortens to every ~2–3 months. forum
Why cyclic, not continuous: Bioregulator theory frames short peptides as gene-expression signals that persist after exposure ends — opposite of continuous BPC-157 injury protocols. forum
Continuous daily: Discussed less often than BPC; generally treated as non-standard versus classic calendars. forum
Re-runs triggers: Seasonal sport load, returning morning stiffness, or scheduled longevity “organ weeks” with other Cytogens. forum
Stack cycle alignment: When stacked with BPC-157, Cartalax often stays as the short cyclic block while BPC runs longer continuous or injury-length courses — mechanisms framed as complementary, not identical schedules. forum
Multi-year gray-market safety: Long-horizon controlled safety datasets for research-powder Cartalax are lacking even when Russian product use is described as long-standing. trial

Timing 7

Class estimate talk: Some chem/vendor sheets estimate extremely short plasma presence for short bioregulators (sometimes cited on the order of tens of seconds to minutes) → daily or split dosing while on-course. Treat as class lore, not a Cartalax-specific PK study. forum
Why short courses anyway: Practice is driven by bioregulator calendars and gene-expression narratives, not by a measured long plasma half-life requiring steady state. forum
Downstream joint feel: Users separate brief blood presence from weeks–months of claimed post-course stiffness/mobility change. anecdote
Avascular cartilage delivery problem: Commentators note cartilage has no direct blood supply, so systemic subq/oral delivery may reach joint tissues poorly — a core uncertainty even if gene-expression data look interesting in vitro. forum
Local vs systemic debate: Local soft-tissue pinning (BPC-style) vs systemic bioregulator calendar vs rare IA ideas — no head-to-head human PK settles the fight for AED. forum
Timing of day: Morning-only or AM/PM multi-mg splits are convenience/chart conventions, not chronotherapy standards. forum
Human PK gap: Modern controlled human half-life, bioavailability, and joint-space concentration data for gray-market Cartalax are sparse to absent. trial

Stacks 12

Cartalax + BPC-157 (most common dual): Bioregulator cartilage calendar + angiogenic/soft-tissue repair — community rationale is different mechanisms; no controlled combo data. Example discussion pattern: Cartalax short cyclic multi-mg or mid-mg block + BPC ~250–500 mcg (often 1–2× daily) for longer injury windows. forum
Wolverine-adjacent triple: Cartalax + BPC-157 + TB-500/TB4 for mobility + multi-tissue recovery; Cartalax stays the short cyclic piece. forum
GLOW / GHK layer: Longevity-joint blogs sometimes layer Cartalax on top of BPC + TB-500 + GHK-Cu rather than replacing that foundation. forum
Cartalax + TB-500 alone: Cartilage-specific bioregulator + systemic actin/cell-migration peptide — theoretical complementarity only. forum
KPV: Occasional anti-inflammatory peptide stack talk with joint protocols; confounded multi-vial blends appear in comments. forum
Bioregulator packs: With Vesugen (vessels), Sigumir (cartilage-class alternative/adjunct), Epitalon (pineal/longevity), Pinealon (CNS), Ventfort/Cerluten in product FAQ-style multi-organ weeks. forum
Sigumir vs/with Cartalax: Product literature treats them as related cartilage-axis options (Sigumir more specialized cartilage; Cartalax broader musculoskeletal/bone-cartilage) — sometimes alternative, sometimes combined in clinic marketing. forum
Collagen peptides / bone broth: Continuous collagen (community often ~10–20 g/day) as “building blocks” while Cartalax is the cyclic signal — confounded nutrition stack. forum
Micronutrient joint stack: Vitamin C, manganese, glucosamine/chondroitin, omega-3s appear in lifestyle sidebars next to Cartalax protocols. forum
PT / deload / load management: Physical therapy, strength balance, weight management, and deloads are frequently credited alongside any peptide “win.” forum
Same-vial blends (anecdote): Users report blending BPC/TB4/KPV/Cartalax in one vial — convenience practice with unknown stability/compatibility; not a studied formulation. anecdote
Injection-site note when stacking: Healing-peptide guides often suggest separate subq sites if multiple injectables are used the same day. forum

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 14

Injection site: Redness, itch, stinging, or mild swelling — most common community report; worse with cold solution, poor technique, or same-site repeats. forum
GI / nausea: Mild nausea at higher multi-mg daily totals in a minority of logs. forum
Headache / dizziness / fatigue: Transient headache (sometimes first 1–2 days), lightheadedness, or drowsiness — causality often unclear with multi-peptide stacks. forum
Blood pressure: Occasional caution/monitoring talk for hypertensive users; no systematic BP trial dataset for Cartalax. forum
“Minimal sides” marketing: Product and vendor language often claims excellent tolerability; absence of loud adverse reports ≠ long-term human safety proof. forum
Senescence / tumor-suppressor theory caution: Mechanistic talk about downregulating p16/p21/p53-class markers leads some commentators to flag active cancer history or strong cancer predisposition as a reason for extra caution — theoretical, not outcome-trial proven harm or safety. forum
Pregnancy / breastfeeding: Not studied; standard research-peptide avoid language. forum
Source quality: Contamination, underdosing, mislabeling, and especially mg-vs-mcg chart confusion on gray markets. forum
Form confusion: Treating oral Cytogen capsules as equivalent to 10 mg injectable AED powder (or vice versa) invalidates log comparisons. forum
Delivery uncertainty: Avascular cartilage may limit systemic peptide access to joint targets; systemic “cartilage repair” claims should be discounted accordingly. forum
Legal / regulatory: Research chemical / parapharmaceutical status varies by country; not an approved OA disease-modifying therapy in major Western regulators. forum
Expectation risk: Users expecting BPC-speed pain relief or MRI-visible cartilage regrowth are common disappointed non-responders. forum
Evidence gap: Sparse modern controlled human efficacy and safety data — Russian observational and in-vitro signals do not equal FDA-level OA proof. trial
Not risk-free: Short-course bioregulator culture and “amino acids only” framing do not remove purity, infection (injectable), or unknown long-horizon risks. forum

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 14

Doses people talk about 14

How it may feel 8

Cycles people discuss 9

Timing 7

More on what it is 8

Stacks 12

Storage notes 2

Related 8

Watch for 14

Timing context & sources